# A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

> **NCT03006068** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 950 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** Upadacitinib (ABT-494)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03006068
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-01-31
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 950 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006068, "A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03006068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*